Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.

Related Keywords

Dublin , Ireland , Ryan Weispfenning , Rachel Murray , Rossj Jr , Jeffrey Popma , Medtronic , Exchange Commission , Our Mission , Renal Denervation , Structural Heart , Cardiovascular Portfolio , Commercial Experience , Tavr , Aortic Stenosis , Revolut , Nited States Food And Drug Administration , Coronary Arteries , Aortic Valve Replacement ,